Trends in Pre-CAR-T Attrition in Relapsed/Refractory Multiple Myeloma: Prevalence, Risk Factors, and Outcomes at a Tertiary Academic Medical Center

Andrew J. Portuguese(University of Washington), Andrew J. Cowan(University of Washington Medical Center), Erik L. Kimble(University of Washington), David G. Maloney(Fred Hutch Cancer Center), Natalie Wuliji(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Alexandre V. Hirayama(University of Washington), Rahul Banerjee(University of Washington), Mary Kwok(National Cancer Institute), Mazyar Shadman(University of Washington), Lorenzo Iovino(University of Pisa), Kara I. Cicero(Fred Hutch Cancer Center), Leona Holmberg, Mahnoosh Taheri(Washington State University), Jordan Gauthier(Seattle Cancer Care Alliance)
Blood
November 5, 2024
10.1182/blood-2024-201092
Cited by 0

Related Papers

Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects
|Blood|2001|1.4k
High-dose fractionated total-body irradiation, etoposide and cyclophosphamide for treatment of malignant lymphoma: comparison of autologous bone marrow and peripheral blood stem cells.
|PubMed|1996|645
Global Burden of Multiple Myeloma
|JAMA Oncology|2018|631
Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience
|Advances in Therapy|2017|603
CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results
|Blood|2012|530